1 – 37 of 37
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII
(
- Contribution to journal › Article
-
Mark
High use of pain, depression, and anxiety drugs in hemophilia : more than 3000 people with hemophilia in an 11-year Nordic registry study
(
- Contribution to journal › Article
- 2022
-
Mark
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children : A critical review from the physician's perspective
(
- Contribution to journal › Scientific review
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
- 2020
-
Mark
Direct comparison of two extended half-life PEGylated recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
- 2019
-
Mark
Direct comparison of two extended-half-life recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
- 2017
-
Mark
Comparative burden of arthropathy in mild haemophilia : a register-based study in Sweden
(
- Contribution to journal › Article
-
Mark
Effect of late prophylaxis in hemophilia on joint status : A randomized trial
(
- Contribution to journal › Article
-
Mark
Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients : Results of the INSIGHT case-control study
(
- Contribution to journal › Article
- 2016
-
Mark
Aspects of prophylactic treatment of hemophilia
(
- Contribution to journal › Scientific review
-
Mark
Does the intensity and quality of treatment and not only the factor VIII level influence global hemostasis in patients with hemophilia A?
(
- Contribution to journal › Letter
-
Mark
Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products
(
- Contribution to journal › Article
- 2014
-
Mark
Factor VIII therapy for hemophilia A: current and future issues
(
- Contribution to journal › Scientific review
-
Mark
The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
- 2013
-
Mark
Exploring Anti-FVIII Antibodies in Haemophilia A - Role in In Vitro Haemostasis and Clinical Disease
(
- Thesis › Doctoral thesis (compilation)
- 2012
-
Mark
Origin of Swedish hemophilia A mutations
(
- Contribution to journal › Article
-
Mark
Optimizing joint function : new knowledge and novel tools and treatments
(
- Contribution to journal › Article
- 2009
-
Mark
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
(
- Contribution to journal › Article
- 2001
-
Mark
Somatic mosaicism in hemophilia A: A fairly common event
(
- Contribution to journal › Article
- 2000
-
Mark
Treatment of children with haemophilia in Europe: A survey of 20 centres in 16 countries
(
- Contribution to journal › Article
- 1999
-
Mark
Prenatal diagnosis of haemophilia
(
- Contribution to journal › Scientific review
- 1998
-
Mark
Can haemophilic arthropathy be prevented?
(
- Contribution to journal › Special issue (editor)
- 1997
-
Mark
Identifying carriers at high risk for negative reactions when performing prenatal diagnosis of haemophilia
(
- Contribution to journal › Article
- 1996
-
Mark
Activated protein C resistance as a basis for venous thrombosis.
(
- Contribution to journal › Article
- 1994
-
Mark
High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products [4]
(
- Contribution to journal › Letter
- 1993
-
Mark
Haemophilia : strategies for carrier detection and prenatal diagnosis
(
- Contribution to journal › Article
- 1990
-
Mark
The incidence and distribution of CpG----TpG transitions in the coagulation factor IX gene. A fresh look at CpG mutational hotspots
(
- Contribution to journal › Article
- 1989
-
Mark
How do carriers of hemophilia experience prenatal diagnosis (PND)? : Carriers' Immediate and later reactions to amniocentesis and fetal blood sampling
(
- Contribution to journal › Article
- 1987
-
Mark
How do carriers of hemophilia experience prenatal diagnosis by fetal blood sampling?
(
- Contribution to journal › Article
- 1986
-
Mark
Carrier detection in hemophilia A : a cooperative international study. II. The efficacy of a universal discriminant
(
- Contribution to journal › Article
-
Mark
Carrier detection in hemophilia A : a cooperative international study. I. The carrier phenotype
(
- Contribution to journal › Article
- 1982
-
Mark
Haemophilia A and B--two years experience of genetic counselling and prenatal diagnosis
(
- Contribution to journal › Article
-
Mark
Immunoradiometric assay of inhibitors of antihaemophilic factor A
(
- Contribution to journal › Article
- 1981
-
Mark
F VIII:CAg in Haemophilia A. A comparison between IRMA:s using haemophilic and spontaneous antibodies
(
- Contribution to journal › Article
-
Mark
Inheritable molecular variants of moderate and mild hemophilia A
(
- Contribution to journal › Article
- 1979
-
Mark
Fanconi's anaemia associated with haemophilia A
(
- Contribution to journal › Article